Oxadiazoles have butyrate-specific conditional activity against mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 6, 2016, Pages 3608-3616

  Early, Julie V ^a   Casey, Allen ^a   Martinez Grau, Maria Angeles ^b   Valcarcel, Isabel C Gonzalez ^c   Vieth, Michal ^c   Ollinger, Juliane ^a   Bailey, Mai Ann ^a   Alling, Torey ^a   Files, Megan ^a   Ovechkina, Yulia ^a   Parish, Tanya ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (Spain)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; ACETIC ACID; BUTYRIC ACID; CYCLOSERINE; GLUCOSE; ISONIAZID; ISOVALERIC ACID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; OXADIAZOLE DERIVATIVE; PALMITIC ACID; RIFAMPICIN; CULTURE MEDIUM; MOLECULAR LIBRARY; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CARBON SOURCE; CELL DENSITY; CONTROLLED STUDY; FLUORESCENCE; IN VITRO STUDY; LUMINESCENCE; MASS FRAGMENTOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPTICAL DENSITY; PHENOTYPE; PRIORITY JOURNAL; SIGNAL NOISE RATIO; STEREOSPECIFICITY; ANIMAL; CELL SURVIVAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; CULTURE MEDIUM; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HIGH THROUGHPUT SCREENING; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR LIBRARY; PHARMACOLOGY; PHYSIOLOGY; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION; VERO CELL LINE;

ANIMALS; ANTITUBERCULAR AGENTS; BUTYRIC ACID; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CULTURE MEDIA; GLUCOSE; HIGH-THROUGHPUT SCREENING ASSAYS; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; METABOLIC NETWORKS AND PATHWAYS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OXADIAZOLES; SMALL MOLECULE LIBRARIES; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS;

EID: 84973663827     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02896-15     Document Type: Article

References (54)

1. World Health Organization. 2016. Tuberculosis fact sheet no. 104. World Health Organization, Geneva, Switzerland. http://www.who.int /mediacentre/factsheets/fs104/en/.
2. World Health Organization. 2015. World health statistics 2015. World Health Organization, Geneva, Switzerland.
3. Rhee KY, de Carvalho LP, Bryk R, Ehrt S, Marrero J, Park SW, Schnappinger D, Venugopal A, Nathan C. 2011. Central carbon metabolism in Mycobacterium tuberculosis: an unexpected frontier. Trends Microbiol 19:307-314. http://dx.doi.org/10.1016/j.tim.2011.03.008.
4. de Carvalho LP, Fischer SM, Marrero J, Nathan C, Ehrt S, Rhee KY. 2010. Metabolomics of Mycobacterium tuberculosis reveals compartmentalized co-catabolism of carbon substrates. Chem Biol 17:1122-1131. http: //dx.doi.org/10.1016/j.chembiol.2010.08.009.
5. Marrero J, Trujillo C, Rhee KY, Ehrt S. 2013. Glucose phosphorylation is required for Mycobacterium tuberculosis persistence in mice. PLoS Pathog 9:e1003116. http://dx.doi.org/10.1371/journal.ppat.1003116.
6. Yang X, Gao J, Smith I, Dubnau E, Sampson NS. 2011. Cholesterol is not an essential source of nutrition for Mycobacterium tuberculosis during infection. J Bacteriol 193:1473-1476. http://dx.doi.org/10.1128 /JB.01210-10.
7. Pandey AK, Sassetti CM. 2008. Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci USA105:4376 - 4380. http://dx.doi.org/10.1073/pnas.0711159105.
8. Van der Geize R, Yam K, Heuser T, Wilbrink MH, Hara H, Anderton MC, Sim E, Dijkhuizen L, Davies JE, Mohn WW, Eltis LD. 2007. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proc Natl Acad Sci U S A 104:1947-1952. http://dx.doi.org/10.1073/pnas .0605728104.
9. Munoz-Elias EJ, McKinney JD. 2005. Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat Med 11:638 - 644. http://dx.doi.org/10.1038/nm1252.
10. Munoz-Elias EJ, McKinney JD. 2006. Carbon metabolism of intracellular bacteria. Cell Microbiol 8:10 -22. http://dx.doi.org/10.1111/j.1462-5822 .2005.00648.x.
11. Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S. 2010. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci U S A 107:9819 -9824. http://dx.doi.org/10.1073/pnas .1000715107.
12. Segal W, Bloch H. 1957. Pathogenic and immunogenic differentiation of Mycobacterium tuberculosis grown in vitro and in vivo. Am Rev Tuberc 75:495-500.
13. Sturgill-Koszycki S, Haddix PL, Russell DG. 1997. The interaction between Mycobacterium and the macrophage analyzed by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 18:2558 -2565. http: //dx.doi.org/10.1002/elps.1150181411.
14. Graham JE, Clark-Curtiss JE. 1999. Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS). Proc Natl Acad Sci U S A 96:11554 -11559. http://dx.doi.org/10.1073/pnas.96 .20.11554.
15. Stokes RW, Waddell SJ. 2009. Adjusting to a new home: Mycobacterium tuberculosis gene expression in response to an intracellular lifestyle. Future Microbiol 4:1317-1335. http://dx.doi.org/10.2217/fmb.09.94.
16. Rohde KH, Abramovitch RB, Russell DG. 2007. Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe 2:352-364. http://dx.doi.org/10 .1016/j.chom.2007.09.006.
17. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, Dolganov G, Efron B, Butcher PD, Nathan C, Schoolnik GK. 2003. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: insights into the phagosomal environment. J Exp Med 198:693-704. http://dx.doi.org/10.1084/jem.20030846.
18. Haydel SE, Clark-Curtiss JE. 2004. Global expression analysis of twocomponent system regulator genes during Mycobacterium tuberculosis growth in human macrophages. FEMS Microbiol Lett 236:341-347. http: //dx.doi.org/10.1111/j.1574-6968.2004.tb09667.x.
19. Rachman H, Strong M, Schaible U, Schuchhardt J, Hagens K, Mollenkopf H, Eisenberg D, Kaufmann SH. 2006. Mycobacterium tuberculosis gene expression profiling within the context of protein networks. Microbes Infect 8:747-757. http://dx.doi.org/10.1016/j.micinf.2005.09.011.
20. Fontan P, Aris V, Ghanny S, Soteropoulos P, Smith I. 2008. Global transcriptional profile of Mycobacterium tuberculosis during THP-1 human macrophage infection. Infect Immun 76:717-725. http://dx.doi.org /10.1128/IAI.00974-07.
21. Tailleux L, Waddell SJ, Pelizzola M, Mortellaro A, Withers M, Tanne A, Castagnoli PR, Gicquel B, Stoker NG, Butcher PD, Foti M, Neyrolles O. 2008. Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. PLoS One 3:e1403. http://dx.doi.org/10.1371/journal.pone .0001403.
22. Honer Zu Bentrup K, Miczak A, Swenson DL, Russell DG. 1999. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 181:7161-7167.
23. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, Swenson D, Sacchettini JC, Jacobs WR, Jr, Russell DG. 2000. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406:735-738. http://dx.doi.org/10.1038/35021074.
24. Upton AM, McKinney JD. 2007. Role of the methylcitrate cycle in propionate metabolism and detoxification in Mycobacterium smegmatis. Microbiology 153:3973-3982. http://dx.doi.org/10.1099/mic.0.2007 /011726-0.
25. Nesbitt NM, Yang X, Fontan P, Kolesnikova I, Smith I, Sampson NS, Dubnau E. 2010. A thiolase of Mycobacterium tuberculosis is required for virulence and production of androstenedione and androstadienedione from cholesterol. Infect Immun 78:275-282. http://dx.doi.org/10.1128 /IAI.00893-09.
26. Liu K, Yu J, Russell DG. 2003. pckA-deficient Mycobacterium bovis BCG shows attenuated virulence in mice and in macrophages. Microbiology 149:1829 -1835. http://dx.doi.org/10.1099/mic.0.26234-0.
27. Shi S, Ehrt S. 2006. Dihydrolipoamide acyltransferase is critical for Mycobacterium tuberculosis pathogenesis. Infect Immun 74:56 - 63. http://dx .doi.org/10.1128/IAI.74.1.56-63.2006.
28. Winder FG, Collins PB. 1970. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J Gen Microbiol 63:41-48. http://dx.doi.org/10.1099/00221287-63-1-41.
29. Takayama K, Wang L, David HL. 1972. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2:29 -35. http://dx.doi.org/10 .1128/AAC.2.1.29.
30. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE, III. 2004. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 279:40174 - 40184. http://dx.doi.org/10.1074 /jbc.M406796200.
31. Maddry JA, Ananthan S, Goldman RC, Hobrath JV, Kwong CD, Maddox C, Rasmussen L, Reynolds RC, Secrist JA, Sosa MI, White EL, Zhang W. 2009. Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb) 89:354 -363. http: //dx.doi.org/10.1016/j.tube.2009.07.006.
32. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, Maddry JA, Mehta A, Rasmussen L, Reynolds RC, Secrist JA, III, Shindo N, Showe DN, Sosa MI, Suling WJ, White EL. 2009. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) 89:334 -353. http://dx.doi.org/10.1016/j .tube.2009.05.008.
33. Miller CH, Nisa S, Dempsey S, Jack C, O'Toole R. 2009. Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. Antimicrob Agents Chemother 53:5279 -5283. http://dx.doi.org/10.1128/AAC.00803-09.
34. Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, Darby C, Jiang X, Warren JD, Fernandez J, Ouerfelli O, Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF. 2012. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad SciUSA109:16004 -16011. http://dx.doi.org/10.1073/pnas.1214188109.
35. Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, Genovesio A, Carralot JP, Ewann F, Kim EH, Lee SY, Kang S, Seo MJ, Park EJ, Skovierova H, Pham H, Riccardi G, Nam JY, Marsollier L, Kempf M, Joly-Guillou ML, Oh T, Shin WK, No Z, Nehrbass U, Brosch R, Cole ST, Brodin P. 2009. High content screening identifies decaprenyl-phosphoribose 2= epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 5:e1000645. http://dx.doi .org/10.1371/journal.ppat.1000645.
36. Stanley SA, Grant SS, Kawate T, Iwase N, Shimizu M, Wivagg C, Silvis M, Kazyanskaya E, Aquadro J, Golas A, Fitzgerald M, Dai H, Zhang L, Hung DT. 2012. Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. ACS Chem Biol 7:1377-1384. http://dx.doi.org/10.1021/cb300151m.
37. Miller CH, O'Toole RF. 2011. Navigating tuberculosis drug discovery with target-based screening. Expert Opin Drug Discov 6:839 - 854. http: //dx.doi.org/10.1517/17460441.2011.586999.
38. Griffin JE, Gawronski JD, Dejesus MA, Ioerger TR, Akerley BJ, Sassetti CM. 2011. High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog 7:e1002251. http://dx.doi.org/10.1371/journal.ppat.1002251.
39. Carroll P, Schreuder LJ, Muwanguzi-Karugaba J, Wiles S, Robertson BD, Ripoll J, Ward TH, Bancroft GJ, Schaible UE, Parish T. 2010. Sensitive detection of gene expression in mycobacteria under replicating and non-replicating conditions using optimized far-red reporters. PLoS One 5:e9823. http://dx.doi.org/10.1371/journal.pone.0009823.
40. Zelmer A, Carroll P, Andreu N, Hagens K, Mahlo J, Redinger N, Robertson BD, Wiles S, Ward TH, Parish T, Ripoll J, Bancroft GJ, Schaible UE. 2012. A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging. J Antimicrob Chemother 67:1948 -1960. http://dx.doi.org/10.1093/jac/dks161.
41. Zhang JH, Chung TD, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73. http://dx.doi.org/10.1177/108705719900 400206.
42. Ollinger J, Bailey MA, Moraski GC, Casey A, Florio S, Alling T, Miller MJ, Parish T. 2013. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. PLoS One 8:e60531. http://dx.doi.org/10.1371/journal.pone.0060531.
43. Lambert RJ, Pearson J. 2000. Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values. J Appl Microbiol 88:784 -790. http://dx.doi .org/10.1046/j.1365-2672.2000.01017.x.
44. Peternel L, Kotnik M, Prezelj A, Urleb U. 2009. Comparison of 3 cytotoxicity screening assays and their application to the selection of novel antibacterial hits. J Biomol Screen 14:142-150. http://dx.doi.org/10.1177 /1087057108329452.
45. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. 1993. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 160:81- 88. http://dx.doi.org/10.1016/0022-1759 (93)90011-U.
46. Eli Lilly and Company. 2004. Assay guidance manual. Eli Lilly and Company and the National Center for Advancing Translational Sciences, Bethesda, MD.
47. Schloss JV, Cleland WW. 1982. Inhibition of isocitrate lyase by 3-nitropropionate, a reaction-intermediate analogue. Biochemistry 21:4420 -4427. http://dx.doi.org/10.1021/bi00261a035.
48. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ. 2012. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) 92:453-488. http://dx.doi.org/10.1016/j.tube.2012.07.003.
49. Rolfe MD, Rice CJ, Lucchini S, Pin C, Thompson A, Cameron AD, Alston M, Stringer MF, Betts RP, Baranyi J, Peck MW, Hinton JC. 2012. Lag phase is a distinct growth phase that prepares bacteria for exponential growth and involves transient metal accumulation. J Bacteriol 194:686 -701. http://dx.doi.org/10.1128/JB.06112-11.
50. Dubos RJ. 1950. The effect of organic acids on mammalian tubercle bacilli. J Exp Med 92:319 -332. http://dx.doi.org/10.1084/jem.92.4.319.
51. Dubos RJ. 1947. The effect of lipids and serum albumin on bacterial growth. J Exp Med 85:9 -22.
52. Pawelczyk J, Brzostek A, Kremer L, Dziadek B, Rumijowska-Galewicz A, Fiolka M, Dziadek J. 2011. AccD6, a key carboxyltransferase essential for mycolic acid synthesis in Mycobacterium tuberculosis, is dispensable in a nonpathogenic strain. J Bacteriol 193:6960 - 6972. http://dx.doi.org/10 .1128/JB.05638-11.
53. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MP, Ujjini M, Rao SP, Camacho L, Bifani P, Mak PA, Ma I, Barnes SW, Chen Z, Plouffe D, Thayalan P, Ng SH, Au M, Lee BH, Tan BH, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T. 2010. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun 1:57. http://dx.doi.org/10.1038 /ncomms1060.
54. Mukesh B, Vandana S. 2011. Antimicrobial activities of 1,3,4-oxadiazole: a review. Int J Res Ayurveda Pharmacy 2:1738 -1742.